StudyFinder
Search Results
1 Study Matches
Site for A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
Atopic Dermatitis: Double Blind, 4 weeks study. Topical Cream applied daily. Males/Females 2-5 years with mild to moderate atopic dermatitis. At the week 4 visit subjects may be eligible to enroll in a 12-month, open label extension study. The goal of the study is assess the safety and effectiveness of ARQ-151 0.05% cream.
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
NCT04844562
SITE00000949
Inclusion Criteria:
Must be 2-5 years of ageExclusion Criteria:
certain medications/treatments are not allowed; study coordinator will discuss furtherSubjects currently undergoing allergy testing (food allergy testing or skin prick testing), patch testing, food challenges, or allergy desensitization, or plan to do so during the study
Skin Conditions